FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 525 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Helping Kids with Cancer Speak for the Supportive Care They Need December 13, 2024 People with Cancer Say Access to Their Clinical Notes Is Valuable November 18, 2020 NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 Reunión anual de la American Society of Clinical Oncology (ASCO) de... June 3, 2022 Load more HOT NEWS Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer EMA Recommends Extension of Indications for Nivolumab Sing Anyway NHL Team Surprises Big Fan Who Spent Breast Cancer Treatment Performing...
